BEIJING (Reuters) -Chinese electric vehicle maker BYD has set a 3.6- million-unit sales target for 2024, a jump of 20% from its record-breaking sales last year, according to three people who were familiar with the matter. The world’s largest EV manufacturer aims to sell 500,000 vehicles overseas this year, more than double last year’s total,… Continue reading Chinese EV maker BYD targets 20% jump in annual sales – sources
Tag: Possible_Terrorism_Warfare
Even The Chinese EV Powerhouse BYD Had To Slow Down A Bit
On Tuesday, BYD Company Limited (OTC: BYDDY) reported its fourth quarter results that included its slowest quarterly profit growth in two years. Even the Tesla Inc (NASDAQ: TSLA) rival who grew from being a battery maker to an EV juggernaut who dethroned Tesla during the last three months of 2023 as the top EV maker, is… Continue reading Even The Chinese EV Powerhouse BYD Had To Slow Down A Bit
With 2 Million Pre-registrations, the Fast-Paced Meme Trading Card Game “Cards Ahoy!” is Officially Live Worldwide
HONG KONG, March 27, 2024 /PRNewswire/ — On March 27, 2024, the landmark Web3 card game “Cards Ahoy !”, developed by Metalist Game, has arrived worldwide and is available now to download and free to play on iOS and Android. Since its beta test, “Cards Ahoy!” has captivated players with its revolutionary gameplay mechanics and rich… Continue reading With 2 Million Pre-registrations, the Fast-Paced Meme Trading Card Game “Cards Ahoy!” is Officially Live Worldwide
Shufersal Group reports results for Q4 and FY 2023: Revenues of ~15.2B NIS and net profit of ~323M NIS
Improvement in the quarterly profit – Shufersal’s net profit for Q4 totaled ~133M NIS, and is an improvement for the company. Improvement in the quarterly profit for the company compared net profits of ~3M NIS in the respective quarter in 2022 Revenues in Q4 grew by ~7%, totaling ~3.9B NIS, compared to ~3.65NIS in the respective… Continue reading Shufersal Group reports results for Q4 and FY 2023: Revenues of ~15.2B NIS and net profit of ~323M NIS
AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production
The partners will work to optimize AQUA Cultured Foods’ fermentation technology and advance the development and production of AQUA’s 100% fish-free products that emulate the look, feel, and taste of fresh-caught seafood CHICAGO and BOSTON, March 27, 2024 /PRNewswire/ — AQUA Cultured Foods, a food tech company producing alternative seafood options through the use of microbial… Continue reading AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production
RFK Jr. Announces VP Pick Is Tech Entrepreneur Nicole Shanahan
“Kennedy’s promise to unravel this corporate capture will help bring an end to this chronic disease epidemic,” Ryerson said. Bhattacharya declared that he was “delighted” that Kennedy has “lent his considerable voice” to the cause of free speech. Bhattacharya is one of the authors of the “Great Barrington Declaration,” an open letter that argued there… Continue reading RFK Jr. Announces VP Pick Is Tech Entrepreneur Nicole Shanahan
EVLV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, March 26, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. (“Evolv” or “the Company”) (NASDAQ: EVLV) and certain of its officers. Class Definition: This lawsuit seeks… Continue reading EVLV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
ROCKVILLE, Md. and SUZHOU, China, March 26, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI310 (anti-CTLA-4 monoclonal antibody) in combination with… Continue reading Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Collagen Market Size to Grow by USD 2.86 billion from 2023 to 2027, Growing demand from the Healthcare industry to boost market growth, Technavio
NEW YORK, March 26, 2024 /PRNewswire/ — The Collagen Market size is estimated to grow by USD 2.86 billion exhibiting a compound annual growth rate (CAGR) of 7.75% between 2022 and 2027. Growing healthcare demand drives market growth. Widely used in medical devices and wound dressings, collagen’s demand rises with aging populations. Technological advances spawn new collagen products, reducing healthcare… Continue reading Collagen Market Size to Grow by USD 2.86 billion from 2023 to 2027, Growing demand from the Healthcare industry to boost market growth, Technavio
Marathon Oil Corporation Announces Pricing of Offering of $600 Million of Senior Notes Due 2029 and $600 Million of Senior Notes Due 2034
HOUSTON, March 26, 2024 /PRNewswire/ — Marathon Oil Corporation (NYSE: MRO) (the “Company”) announced today that it has priced an offering of senior notes in an aggregate amount of $1.2 billion, consisting of $600 million principal amount of its 5.300% Senior Notes due 2029 and $600 million principal amount of its 5.700% Senior Notes due 2034.… Continue reading Marathon Oil Corporation Announces Pricing of Offering of $600 Million of Senior Notes Due 2029 and $600 Million of Senior Notes Due 2034